Article Text

other Versions

Download PDFPDF
Oral rifampin utilisation for the treatment of chronic multifocal central serous retinopathy
  1. Nathan C Steinle,
  2. Naina Gupta,
  3. Alex Yuan,
  4. Rishi P Singh
  1. Department of Ophthalmology, Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA
  1. Correspondence to Dr Rishi P Singh, Cole Eye Institute, Cleveland Clinic Foundation, 9500 Euclid Avenue, i-32, Cleveland OH 44195, USA; singhr{at}


Chronic central serous retinopathy (CSR) is characterised by frequent exacerbations and a poor visual prognosis. Very few therapies exist for chronic CSR, and the existing therapies are often ineffective. Thus, novel therapies to combat this frustrating disorder are needed. Presented here is a case detailing a patient with chronic CSR with persistent subfoveal fluid of 2 years' duration that completely resolved with 1 month of oral rifampin therapy. As a cytochrome P450, 3A4 inducer, rifampin is thought to favourably alter the metabolism of endogenous steroids, thereby leading to an improvement in CSR manifestations.

  • Rifampin
  • central serous retinopathy
  • CYP450
  • 3A4 inducer
  • endogenous steroid metabolism
  • retina
  • vitreous

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests None.

  • Patient consent Obtained.

  • Provenance and peer review Not commissioned; externally peer reviewed.